ClinicalTrials.gg

Program

cofrogliptin

Its studies are mostly in Diabetes Mellitus, Type 2, led by Haisco Pharmaceutical Group.

Furthest: no phase, since Aug 7, 20251 company-led study, 1 open or runningNext primary completion: Jun 30, 2027

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haisco Pharmaceutical Group11 open or runningno phasesince Aug 7, 2025Aug 7, 2025Jun 30, 2027NCT07122102

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 7, 2025First study: no phase study in Diabetes Mellitus, Type 2First studyNCT07122102 · 200 planned · China

Ahead

  1. Jun 30, 2027Primary completion: no phase study in Diabetes Mellitus, Type 2NCT07122102

TargetBeta

DPP4 →read by rule
“Cofrogliptin is a novel, ultra-long-acting DPP-4 inhibitor.”study text, by rule · the study

Other programs on DPP4

ProgramCompanyFurthest phaseStudies
sitagliptinruleMerckphase 4123
LinagliptinruleBoehringer Ingelheimphase 496
gemigliptinruleLG Chemphase 430
anagliptinruleJW Pharmaceuticalphase 46
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07122102Diabetes Mellitus, Type 2 · China–Not yet recruitingJun 30, 2027200

How it is read

Names in the registry

  • “Cofrogliptin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.